Replies to post #151901 on Biotech Values

[acgood]

Alny has not abandoned their pcsk9 program...that was isis. But alny IV lead program is dead IMO...any partner would only want the preclinical subcutaneous version which is helplessly far behind unless a safety concern emerges with the antibodies